Treatment Outcomes in People with Migraine Receiving Rimegepant or Triptans: A Descriptive Analysis from A Real-world Survey
Abraham L, Brown J, Hygge-Blakeman K, Dai F, Jackson J, Whitton W, Barlow S, Hancock L
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Cardiovascular and Cerebrovascular Events During Treatment of Migraine with Rimegepant: Analysis of Post-Authorization Safety Data
Chan A, Fountaine RJ, Pawinski R, Pixton G, Straghan E
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Characteristics of People with Migraine Using Rimegepant in the 2023 U.S. National Health and Wellness Survey
Lewis M, Jenkins A, Cirillo J, Hygge Blakeman K, Abraham L, Brown J, Ailani J
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Long-term Safety and Discontinuation for Rimegepant Versus Triptans: A Matching-adjusted Indirect Comparison
Powell L, de Brun C, Rogula B, Jenkins A, Atkinson J, Abraham L
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Efficacy and Safety of Rimegepant 75 mg for Acute Treatment of Migraine: A Pooled Analysis of 4 Randomized, Placebo-Controlled Trials
Tepper SJ, Pavlovic JM, Yu S, Lipton RB, Pixton G, Zou Y, Fountaine RJ, Semel D
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Rimegepant for the Acute Treatment of Migraine: A Phase 3, Multicenter, Open-Label, Long-Term Safety Study in Adults from China
Yu S, Ma L, Zhong Q, Han X
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in Monthly Migraine Days: A Pooled Analysis of 2 Open-Label Trials
Yu S, Fullerton T, Pixton G, Zou Y, Zhong Q, Zhu H
MTIS 2024
- 偏头痛信托国际研讨会 2024
| 偏头痛 | 乐泰可
